Navigation Links
Side Effects of Sunitinib in Kidney Cancer Are 2 to 3 Times More Expensive to Manage Than Those of Avastin Plus Interferon
Date:5/30/2008

- Tolerability is an Increasingly Important Factor When Selecting Treatment

Options for Patients

- ABSTRACT No: 5110 (Poster 6H)

BASEL, Switzerland, May 30 /PRNewswire/ -- Data presented at the largest oncology meeting in the world, the American Society of Clinical Oncology (ASCO), shows that the costs of managing side effects in patients with metastatic renal cell cancer (mRCC) treated with sunitinib (Sutent(R)) are two to three times greater than if they were treated with the combination of Avastin and interferon (IFN), a combination which provides comparable patient efficacy to sunitinib.

Avastin + IFN has already been shown to significantly prolong the time patients with mRCC live without their disease getting worse (progression-free survival; PFS). The Avastin-based therapy patient benefit is comparable in terms of PFS to sunitinib, but the treatment regimens have very different side effect profiles. The study conducted in Germany, France and the UK suggests that the increased cost of managing the side effects seen with sunitinib is mainly due to the higher incidence of low blood cell counts, diarrhea and nausea/vomiting seen with sunitinib.

"Side effects are a very important consideration for both doctors and patients when making treatment decisions particularly with new treatments providing longer periods of time without advancement of disease," said Professor Gerald Mickisch, from the Center of Operative Urology, Academic Hospital Bremen in Germany, and author of the study. "Given the cost of managing side effects, tolerability is also an important consideration for healthcare payers."

Earlier results from the Avastin in Renal (AVOREN) study also showed that reducing the dose of IFN did not appear to affect the efficacy of the Avastin and IFN combination which may lead to lower cumulative toxicity than other available treatments for patients with advanced RCC. In contrast, data presented at ASCO 2007 suggest that the dose of sunitinib needs to be maintained long-term in order to maintain efficacy.

Further data from patient sub-group analysis of AVOREN are also being presented at ASCO this year which will show that Avastin is effective at improving the time patients live without their disease advancing across a wide range of patient types.

Avastin was approved in Europe in December 2007 for use in combination with IFN in the first-line treatment of patients with advanced renal cell cancer.

About the AVOREN Study

The AVOREN study is a randomised, controlled, double-blind, phase III study that included 649 patients with advanced kidney cancer from 101 study sites across 18 countries. Study participants received treatment with either Avastin and IFN alpha-2a or placebo and IFN alpha-2a, the standard of care in patients with advanced kidney cancer.

The results of the AVOREN trial showed that by adding Avastin to IFN:

- Progression free survival (PFS) was almost doubled from a median of 5.4 to 10.2 months

- Tumour response was significantly increased from 12.8% with IFN alone to 31.4% when Avastin was added

- Dose-reduction of IFN did not appear to affect the efficacy of the combination with Avastin (based on PFS event free rates over time, as shown by a sub-group analysis)

The study also showed a trend towards improved overall survival; however, full survival data are expected during the second half of 2008. No new or unexpected adverse events were observed.

Additional information

- Roche in Oncology: http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

- Roche Health Kiosk, Cancer: http://www.health-kiosk.ch/start_krebs

- Avastin: http://www.avastin-info.com

To access video clips about Avastin in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com .


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Prostate Cancer Treatment Offers Results Without Side Effects
2. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
3. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
4. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
5. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
6. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
7. High Blood Pressure May Heighten Effects of Alzheimers Disease
8. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
9. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
10. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):